FNCH
Finch Therapeutics Group Inc (FNCH)
$0.93
Market is closedMarket is closed – opens on 8 PM, 07 Dec 2022
– opens on 8 PM, 07 Dec 2022
Key Stats
$0.92
Day's Range
$0.99
$0.83
52-Week Range
$14.87
| Returns | |
| 1 month return | 24.59% |
| 3 month return | 62.74% |
| 1 year return | 91.34% |
| 5 year return | 95.54% |
Company Information
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.
| Organization | Finch Therapeutics Group Inc |
| Employees | 189 |
| CEO | Dr. Mark Burnham Smith Ph.D. |
| Industry | Healthcare |
Analyst Recommendation
based on 3 analysts ratings
Buy
100%
Buy
0%
Hold
0%
Sell
Based on 3 Wall street analysts offering stock ratings for Finch Therapeutics Group Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 1324.73%Current
$0.93
Target
$13.25
Recommendation Trend
Based on 3 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 3 | 9 | 8 |
| Hold | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 45.5M |
| Book Value | $2.53 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -1.44 |
| Wall Street Target Price | 13.25 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.38 |
| Enterprise Value | 13.0M |
| Enterprise Value/Revenue | 7.86 |
| Enterprise Value/Ebitda | -0.16 |
Technicals
| 50 Day MA | 1.35 |
| 200 Day MA | 2.88 |
Institutional Holdings
Susquehanna International Group, LLP
3.7%
Avenir Management Co., LLC
3.47%
Baupost Group LLC
2.34%
Vanguard Group Inc
2.11%
Bleichroeder LP
1.69%
LAKE STREET ADVISORS GROUP, LLC
1.54%
Discover more
Frequently Asked Questions
What is Finch Therapeutics Group Inc share price today?
Can Indians buy Finch Therapeutics Group Inc shares?
How can I buy Finch Therapeutics Group Inc shares from India?
Can Fractional shares of Finch Therapeutics Group Inc be purchased?
What are the documents required to start investing in Finch Therapeutics Group Inc stocks?
What are today’s High and Low prices of Finch Therapeutics Group Inc?
What are today’s traded volumes of Finch Therapeutics Group Inc?
What is today’s market capitalisation of Finch Therapeutics Group Inc?
What is the 52 Week High and Low Range of Finch Therapeutics Group Inc?
How much percentage Finch Therapeutics Group Inc is down from its 52 Week High?
How much percentage Finch Therapeutics Group Inc is up from its 52 Week low?
What are the historical returns of Finch Therapeutics Group Inc?
Who is the Chief Executive Officer (CEO) of Finch Therapeutics Group Inc?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*